1. The liposomal formulation comprising: (a) fragments strain complex Mycobacterium tuberculosis (MTB-C), (b) an agent forming the liposome, (c) 1-20% (w / v..) Sucrose, preferably 2-12 % (wt. / vol.) sucrose, more preferably 3-8% (wt. / vol.) sucrose, and most preferably 4-6% (wt. / vol.) sucrose, wherein z-average particle size is 120 nm or menee.2. The liposomal preparation according to claim 1 wherein the z-average particle size is in the range of 40 to 110 nm, and more preferably from 55 to 95 nm.3. The liposomal drug according to any one of claims 1 or 2, wherein said liposomal preparation is an emulsion, and wherein the z-average particle size is preferably less than 40 nm.4. The liposomal preparation according to Claim. 1, wherein the polydispersity index of the particles is 0.4 or less, preferably, 0,3.5. The liposomal preparation according to Claim. 1, wherein the strain complex Mycobacterium tuberculosis (MTB-C) is a virulent strain complex Mycobacterium tuberculosis (MTB-C), preferably, the strain of MTB-C NCTC 13536, deposited at NCTC 2010, in a Londone.6. The liposomal formulation of claim 1 which further comprises:. (D) tenzioaktivny agent, and / or (e) one or more nonionic surfactants veschestv.7. The liposomal preparation according to Claim. 1, where pieces of MTB-C cells are or contain cell fragments stenki.8. The liposomal formulation of claim 6, wherein the ratio of (a) to (d) is 0.05:. 1-1: 5 (w / w..). 9. The liposomal preparation according to Claim. 1, wherein said agent forming a liposome is a hydrogenated, partially hydrogenated or non-hydrogenated phospholipid, preferably lecithin, most preferably, soy letsitin.10. The liposomal formulation of claim. 6 tenzioaktivny wherein said agent is selected from cholate, deoxycholate1. Липосомный препарат, содержащий:(a) фрагменты штамма комплекса Mycobacterium tuberculosis (MTB-C),(b) агент, образующий липосому,(с) 1-20% (мас./об.) сахарозы, предпочтительно, 2-12% (мас./об.) сахарозы, более предпочти
